NanoViricides, Inc. (NASDAQ:NNVC) | Finanzwire

Basculer en Français

8296	Companies
114905	Keywords
55332	Articles
62461	Press releases

Home
Companies
NanoViricides, Inc.

BRIEF

published on 11/15/2024 at 12:35, 6 days 1 hour ago

NanoViricides Advances NV-387 to Phase II Trials for Multiple Viral Infections

NanoViricides NV-387 Financial Report Clinical Trials Antiviral Drug
PRESS RELEASE

published on 11/15/2024 at 12:30, 6 days 1 hour ago

NanoViricides, Inc. Has Filed its Quarterly Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include MPOX/Smallpox, RSV, Influenza, COVID
NanoViricides, Inc. files Quarterly Report on Form 10-Q with the SEC, highlights financial results and progress on NV-387 antiviral drug for various infections including MPox and RSV

NanoViricides NV-387 Quarterly Report SEC Filing Antiviral Drug
BRIEF

published on 11/04/2024 at 06:05, 17 days 7 hours ago

NanoViricides Presents at Spartan Capital Investors Conference 2024

NanoViricides NV-387 Antiviral Nanomedicines Spartan Capital Conference Dr. Anil R. Diwan
PRESS RELEASE

published on 11/04/2024 at 06:00, 17 days 7 hours ago

NanoViricides to Provide Corporate Update at the Spartan Capital Investors Conference 2024, Today at 9:45am
NanoViricides, Inc. to present corporate update at Spartan Capital Investors Conference on NV-387 antiviral drug development with strong market potential

NV-387 NanoViricides Inc. Market Potential Antiviral Drug Spartan Capital Investors Conference
BRIEF

published on 10/22/2024 at 12:35, 30 days 1 hour ago

NanoViricides President to Present at PODD Conference

NanoViricides NV-387 Drug Delivery PODD Conference Antiviral Treatments
PRESS RELEASE

published on 10/22/2024 at 12:30, 30 days 1 hour ago

NanoViricides President Dr. Diwan to Present at the PODD Conference
NanoViricides announces President Dr. Anil R. Diwan to speak at PODD Conference about revolutionary antiviral nanomedicines. Conference focuses on drug delivery partnerships and trends

NanoViricides Drug Delivery Antiviral Nanomedicines PODD Conference Anil R. Diwan
BRIEF

published on 10/15/2024 at 12:35, 1 month 6 days ago

Innovative Antiviral Technology Discussed in Recent NanoViricides Podcast

NanoViricides NV-387 Antiviral Treatment Phase II Trials Nanomedicine Technology
PRESS RELEASE

published on 10/15/2024 at 12:30, 1 month 6 days ago

NanoViricides President Dr. Diwan Interviwed in PODD Podcast; He Explains the Revolutionary Clinical Stage Broad-Spectrum Antiviral NV-387, and the Potential of the Platform to Revolutionize Fields Beyond Virology
NanoViricides, Inc. announces interview with Dr. Diwan discussing revolutionary broad-spectrum antiviral clinical drug candidate NV-387 and innovative nanoviricide technology platform

NV-387 Clinical Trials NanoViricides Inc. Antiviral NanoViricides Technology
BRIEF

published on 10/08/2024 at 12:35, 1 month 13 days ago

NanoViricides to Address AMR Summit 2024 on Innovative Drug Technologies

Antimicrobial Resistance Clinical Trials AMR Summit 2024 NanoViricides Technology NV-387 Drug
PRESS RELEASE

published on 10/08/2024 at 12:30, 1 month 13 days ago

NanoViricides to Present at the Global AMR Summit 2024 Tomorrow
Dr. Diwan to discuss NanoViricides' pathogen-directed attack technology combating AMR at the Global AMR Summit, highlighting the 'shape-shifting' nanoviricide platform

NanoViricides Antiviral AMR Nanomedicines Pathogen-directed Therapy

1 2 ... 8

Accesswire

Published on 11/21/2024 at 13:30, 29 minutes ago

AirIQ Announces September 30, 2024 Quarterly Results Company Reports Double-Digit Growth in Recurring Revenue
Published on 11/21/2024 at 13:30, 29 minutes ago

Datametrex Secures Additional P.O. Approx $250K for IT Services
Published on 11/21/2024 at 13:00, 59 minutes ago

Aclara Secures Funding from Corfo's Innovation High-Tech Program for Artificial Intelligence Project
Published on 11/21/2024 at 13:00, 59 minutes ago

Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1
Published on 11/21/2024 at 13:00, 59 minutes ago

Toggle3D.ai Rebrands as FOTOgpt.ai to Usher in a New Age of AI-Powered Photography

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 13:15, 44 minutes ago

NOTICE OF ANNUAL GENERAL MEETING
Published on 11/21/2024 at 12:35, 1 hour 24 minutes ago

audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 12:15, 1 hour 44 minutes ago

Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 12:06, 1 hour 52 minutes ago

IVU AG publishes Quarterly Report Q3-2024
Published on 11/21/2024 at 12:00, 1 hour 59 minutes ago

Holding(s) in Company

Les Echos

Published on 11/21/2024 at 06:58, 7 hours 1 minute ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 18 hours 39 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 20 hours 14 minutes ago

MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 20 hours 14 minutes ago

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 6 hours ago

Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo

View all LES ECHOS COMFI WIRE